

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5663065

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BRUCE YONG MA	06/12/2019
YU FAN	06/12/2019
ANLIANG WANG	06/12/2019
JUN WANG	06/12/2019
RECEIVING PARTY DATA	
Name:	ZONHON BIOPHARMA INSTITUTE, INC
Street Address:	3 FL, BUILDING 2, NO. 518, YUNHE ROAD
Internal Address:	XINBEI DISTRICT
City:	CHANGZHOU, JIANGSU
State/Country:	CHINA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16474217
CORRESPONDENCE DATA	
Fax Number:	(203)220-8497
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2032208496
Email:	dilworthip@dilworthip.com
Correspondent Name:	DILWORTH IP LLC
Address Line 1:	2 CORPORATE DRIVE
Address Line 2:	SUITE 206
Address Line 4:	TRUMBULL, CONNECTICUT 06611
ATTORNEY DOCKET NUMBER:	423-002US
NAME OF SUBMITTER:	JESSICA K. BUTCHKO, PARALEGAL
SIGNATURE:	/Jessica K. Butchko, Paralegal/
DATE SIGNED:	08/12/2019
Total Attachments: 2	
source=423-002US_EXECUTED_Assignment#page1.tif	
source=423-002US_EXECUTED_Assignment#page2.tif	

ASSIGNMENT OF INVENTION (US ONLY)

WHEREAS, we, Bruce Yong MA, Yu FAN, Anliang WANG and Jun WANG (the "Assignors"), have made an invention entitled:

**RECOMBINANT DERMATOPHAGOIDES PTERONYSSINUS TYPE 2 ALLERGEN
PROTEIN AND ITS PREPARATION METHOD AND APPLICATION**

filed as US Patent Application No. 16/474,217 on July 27, 2019, as the national phase of PCT/CN2017/119173 filed on December 28, 2017 claiming priority to Chinese Patent Application No. 201611267033.8 filed on December 31, 2016.

WHEREAS, ZONHON BIOPHARMA INSTITUTE, INC having an address at 3 FL, Building 2, No. 518, Yunhe Road, Xinbei District, Changzhou, Jiangsu China (the "Assignee"), is desirous of acquiring the entire right, title and interest in and to the aforesaid invention, including any tangible materials embodied in or encompassed by the invention, and any improvements thereon, (the "Invention") and in and to applications for Letters Patent thereon in the United States, its territories and possessions ("United States"), including rights to claim priority, to any provisional applications, and in and to any Letters Patent of the United States which may be granted therefor, including any and all reissues, divisionals, continuations, continuations-in-part, renewals, substitutes or extensions thereof (the "Rights");

NOW, THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged, Assignors have sold, assigned, transferred and conveyed, and do hereby sell, assign, transfer and convey to Assignee, their successors and assigns, the entire right, title and interest in and to the aforesaid Invention and Rights. The aforesaid assignment includes the right in and to all income, royalties, damages and payments now or hereafter due or payable with respect to any Letters Patent which may be granted, and in and to all causes of action (either in law or in equity), and the right to sue, counterclaim, and recover for past, present and future infringement of the rights assigned or to be assigned under this Assignment, as fully and entirely as the same would have been held and enjoyed by Assignors if this sale and assignment had not been made;

AND Assignors hereby authorize and request the appropriate governmental officials to issue any and all such United States Letters Patent under said Invention, or resulting from any of said applications therefor, to the Assignee, as the assignee of the entire right, title and interest in and to the same;

AND Assignors hereby represent, warrant and covenant that they have the full right to convey the entire interest herein assigned, that they have not executed and will not execute any instrument or assignment in conflict herewith, and that the rights assigned herein are not otherwise encumbered by any grant, license or right;

AND Assignors further covenant and agree that Assignors will at any time upon request make, execute and deliver without further compensation, any and all other instruments in writing, including further applications, papers, affidavits, powers of attorney, assignments, and other

documents, and do all lawful acts and things, which, in the opinion of counsel for said Assignee, their successors and assigns, may be required or necessary more effectively to secure to and vest in said Assignee, their successors and assigns the entire right, title and interest in and to said Invention and Rights hereby sold, assigned, transferred and conveyed, and that Assignors will sign any applications for reissue, divisional, continuation, continuation-in-part, renewal, substitute or extension of said application for Letters Patent or any resulting Letters Patent;

AND Assignors further covenant and agree that Assignors will at any time upon request communicate to the Assignee, their successors, assigns or other legal representatives any facts relating to the aforesaid Invention known to them, and will testify as to the same in any post grant proceeding, litigation, mediation, arbitration or other proceeding when requested to do so.

In witness whereof, executed by the undersigned on the dates below.

Assignors:

Date: June 12, 2019 Signature: 
Bruce Yong MA

Date: 2019.6.12 Signature: YU FAN
Yu FAN

Date: 2019-6-12 Signature: Anliang Wang
Anliang WANG

Date: 2019-6-12 Signature: Jun WANG
Jun WANG

Assignee:

ZONHON BIOPHARMA INSTITUTE, INC

By: Yifei Chen

Name: Yifei Chen

Title: IP supervisor

Date: 2019.6.12